13ACKGI~OUND: Subacute combined degeneration is an acquired myelopathy caused by vitamin B12 deficiency. Therapy with B12 leads to improvement in most but to complete recovery in only a few patients. Prognostic indicators in subacute combined degeneration are unknown; therefore, predicting complete recovery of neurologic deficits is challenging.
degeneration of the spinal cord. 1.2 Subacute combined degeneration is a rapidly progressive myelopathy that can be associated with profound neurologic deficits including progressive sensory abnormalities, ascending paresthesias, weakness, ataxia, loss of sphincter control, and gait impairment.l-7 In some patients with vitamin B12 deficiency, subacute combined degeneration can be triggered by brief exposure to nitrous oxide during anesthesia s-l° and in others after prolonged recreational use of the drug. 11 Pathologically, the disease is characterized by astrogliosis, normal oligodendroglia, and normal neurons. 12 Subacute combined degeneration used to be a common devastating disease but the elucidation of its etiology has led to therapeutic and prophylactic use of B 12, which likely has decreased its prevalence, l a- 15 It is surprising, however, that despite improvement in diagnostic tools, such as magnetic resonance imaging (MRI), and effective therapy, data on prognostic indicators and predictors of complete resolution of neurologic deficits in subacute combined degeneration are sorely lacking. When treating the disease, physicians are unable to predict whether a patient will have complete resolution or only improvement of the disabling neurologie deficits. Therefore, in this study, we sought to identify clinical, laboratory, and radiological factors present at the time of diagnosis that could potentially correlate with resolution of neurologic deficits in patients with subacute combined degeneration.
METHODS

Data Source
We searched EMBASE (1974 to October 2005) and MEDLINE (1968 to October 2005), scanned references from all included reports using MeSH headings (vitamin B 12 deficiency, pernicious anemia, nitrous oxide), subheadings (complications, pathology, diagnosis, classification), and keywords (subacute combined degeneration and cobalamin). We also included data from a patient treated by the authors.
Reports Selection
We selected reports of patients with m subacute combined degeneration that described results of MRI and patient's outcome after B12 therapy. We included patients who met the following criteria16: (1) confirmed by MRI studies, (2) evidence of vitamin B12 deficiency, and (3) absence of identifiable pathology of the central or peripheral nervous system that could account for the clinical picture. Patients with preexistent or concomitant neurologic pathology (multiple sclerosis, tumors) described in the history or suggested by MRI were excluded.
Data Extraction
We extracted demographic, clinical, laboratory, and radiologic data. Potential predictive factors (variable) and outcome (complete resolution or improvement only) were reviewed independently by 2 neurologists (O.M.V. and E.H.P.) using preformatted coded case report forms. Discrepancies between data fields occurred in 2 instances and were related to reports written in a foreign language. These discrepancies were addressed with a translator and joint review of the manuscripts. As all reports identified in the literature only described patients who improved with B12 therapy, clinical outcomes were defined as improvement (arrest of disease progression followed by improvement but persistence of neurologic deficits) or complete resolution (arrest of disease progression followed by complete resolution of neurologic deficits). We evaluated the quality of the reports by assessing the accuracy of diagnosis, appropriateness of therapy, and report of clinical, laboratory, and radiological variables, and clinical outcome.
Data Synthesis and Analysis
Data from 57 patients were used to estimate the strength of association between 18 clinical, laboratory, and radiologic factors ( Table 1 ) and resolution of signs and symptoms in patients with subacute combined degeneration. We calculated rates of complete resolution for patients with and without each of the study factors, complete clinical resolution rate differences between patients with and without factors, and their 95% confidence limits. The strength of the association is indicated by the magnitude of the difference in complete resolution rates between patients with and without a given factor. Whether the association is statistically different from 0 is indicated by whether the 95% confidence interval includes 0 or not. Statistical analyses were conducted using MIX version 1.1 software. 17
RESULTS
Literature Search
We identified 239 potentially relevant reports and eliminated 194 lacking case studies, confirmed diagnosis, patient outcome, or MRI data. Although we searched the literature since 1968, the earliest report containing MRI data was from 1991.18 Forty-five reports described 57 patients with subacute combined degeneration who met inclusion criteria.9-11.18-59
Patient Treated by the Authors
A 36-year-old male developed paresthesias and gait disturbance after general anesthesia including nitrous oxide. Symptoms and signs included leg weakness, erectile dysfunction, impaired bowel and bladder control, spastic quadriparesis, diffuse hypereflexia, extensor plantar responses, ataxic-paretic gait, Romberg sign, proprioceptive and vibratory sensory loss in the legs, and sensory deficit to T5. Laboratory studies showed macroeytic anemia and low serum B12. Spine MRI showed increased T2-weighted signal intensity of posterior columns and low Tl-weighted signal intensity in the bone marrow ( Fig. 1 , available online, A, B, and E). Treatment with B 12 yielded clinical and MRI improvement (Fig. 1 , C, D, and F) and at 21-month follow-up, distal sensory deficits persisted and spine MRI showed residual patches of high T2-weighted signal intensity of posterior columns.
Clinical, Laboratory, and Radiologic Profile
The mean age of patients who had complete resolution of signs and symptoms after B12 therapy was 39.8 ± 18.8 and that of patients who only improved was 55.9 + 15.5 years (mean ± SD). The median duration of illness at the time of diagnosis was 6 weeks (range 2 to 24 weeks) in patients who had complete resolution and 12 (range 1 to 84 weeks) in patients who only had improvement with B12 therapy. Of 57 patients, 43 (75%) had pernicious anemia, 3 were vegans (5%), and 10 (17.5°/o) had other identifiable risk factors for B12 deficiency. Only 1 patient had no reported risk factor for B 12 deficiency. In 15 patients, exposure to nitrous oxide preceded the development of subacute combined degeneration (during surgical procedures or chronic recreational use). Reported signs and symptoms included symmetric ascending paresthesias, sensory loss, muscle weakness, ataxta, and gait abnormalities. Sensory deficit in a stocking glove distribution pattern and sharp spinal level (from C2 to T11) were reported. Tendon reflex abnormalities were ubiquitous and ranged from generalized hypereflexia with clonus to absent reflexes. Dissociation between upper (hyperactive) and lower (decreased or absent) extremity reflexes was reported frequently. In lower limbs, coexistence of hyperactive knee responses and hypoactive or absent ankle jerks was commonly observed. Sphincter dysfunction was present in a few patients. Of 57 patients, over 85% had anemia, macrocytosis, and decreased vitamin B12 levels (data not shown). On MR[, several patterns were described: focal or small cord lesions involving few contiguous levels (_< 7 segments, N=29); extensive linear abnormalities (_> 8 segments, n=22), and scattered small multifocal lesions (N=2). Increased T2-weighted signal intensity in dorsal columns was the most common fmding.
After initiation of B12 therapy, all patients reported in the literature showed, at a minimum, arrest of progression of neurologic deficits. Of 57 patients included in the analysis, 49 (86%) improved and 8 (14%) had complete resolution of signs and symptoms. Resolution of radiological abnormalities on follow-up scans occurred in 5 of 8 subjects who had complete resolution of deficits. Conversely, in a few patients, follow-up MRI normalized despite persistence of neurologic deficits (paresthesias and sensory loss). In 2 subjects, clinical resolution preceded normalization of spine MRI findings. In these 2 cases, follow-up scan was obtained 12 to 24 weeks after the first study. In 2 subjects with segmental atrophy of the thoracic spinal cord, B 12 therapy led to symptomatic improvement but no appreciable functional gain. Among 10 patients with extensive linear cord injury (> 20 segments), only 1 (10-year-old male) had complete resolution of deficits after B12 therapy. 
*N represents the number of patients reported to have the findings as described at the time of diagnosis and n, the number of patients who had those findings and achieved complete resolution of signs and symptoms after treatment with B12. Anemia was defined as a hemoglobin level below and macrocytosis as a mean corpuscular volume above the normal reference range of the reporting institution. The strength of association between a given finding and complete clinical resolution is indicated by the magnitude of the difference in complete resolution rates between patients with and without a given factor.
Possible Correlates of Outcome
Possible correlates of outcome in patients with subacute combined degeneration and their respective magnitude of association are shown in Table 1 . As indicated by the magnitude of differences in clinical resolution rates, factors showing a strong association with complete resolution of signs and symptoms include absence of sensory level, Romberg and Ba- binski sign, a n d spinal cord atrophy. In addition, the male gender, absence of anemia, presence of Lhermitte's sign, a n d age < 50 years were also strongly associated with complete resolution of signs a n d symptoms in subacute combined degeneration.
DISCUSSION
While several medical specialties are likely to evaluate patients with s u b a c u t e combined degeneration, little information on predictors of outcome is available. 1,2,6o-62 In this investigation, we used published d a t a to generate h y p o t h e s e s regarding potential correlates of outcomes a n d found t h a t clinical, laboratory, a n d MRI findings at the time of diagnosis may correlate with complete resolution of signs a n d symptoms in s u b a c u t e combined degeneration. However, the fact t h a t we found no reports of patients with s u b a c u t e combined degeneration who failed to improve after t h e r a p y limits o u r conclusions to only those patients who respond to B12 therapy. We acknowledge t h a t patients who do not r e s p o n d to therapy, a n d have not b e e n reported in the literature, m a y have similar characteristics. Our findings suggest t h a t a b s e n c e of sensory level, Romberg a n d Babinski signs may be associated with clinical resolution of signs a n d symptoms in patients with s u b a c u t e combined degeneration. It is k n o w n t h a t the presence of sensory level reflects spinal cord damage t h a t i n t e r r u p t s t r a n smission of sensory impulses to higher centers in the central nervous system, Romberg sign reflects blockade of deep sensory impulses from lower extremities a n d severe compromise of heavily myelinated sensory axons along the posterior colu m n s , a n d t h a t Babinski sign reflects damage to corticospinal tract fibers traveling in the lateral funiculi of the spinal cord. Therefore, it is conceivable t h a t patients without sensory level, Romberg, a n d Babinski signs have less severe disease a n d therefore a higher likelihood of achieving complete resolution of neurologic deficits with B12 therapy.
Our study suggests t h a t age < 50 years is associated with a higher complete resolution rate of signs a n d s y m p t o m s in s u b a c u t e combined degeneration. This is not surprising as younger patients have greater nervous system plasticity. The report of a 10-year-old who recovered despite extensive spinal cord involvement further s u p p o r t s this hypothesis. 23 Also, at the time of diagnosis, patients who h a d complete resolution of signs a n d symptoms with B12 therapy h a d a shorter d u r a t i o n of illness compared with those who only improved. Therefore, our findings s u p p o r t the notion t h a t younger age and, as previously suggested by others, 3 shorter d u r a t i o n of illness positively impact on the likelihood of reaching complete resolution with B12 in s u b a c u t e combined degeneration.
The reports indicate t h a t s u b a c u t e combined degeneration is associated with heterogeneous p a t t e r n s on MRI, suggesting t h a t the disease m a y b e a c o n t i n u u m --f o c a l areas of demyelination gradually coalesce into larger spinal cord lesions as described in neuropathologic studies. 12 We found t h a t involvement of 7 or less spinal cord segments, presence of spinal cord edema, a n d / o r contrast e n h a n c e m e n t , b u t not cord atrophy, were associated with higher resolution rates in patients with s u b a c u t e combined degeneration. These findings s u p p o r t the notion t h a t patients with less severe spinal cord involvement on MRI are likely to have less severe disease a n d therefore higher resolution rates after B 12 treatment. Another interesting observation was t h a t in a few patients, resolution of clinical signs a n d symptoms preceded normalization of MRI abnormalities. This suggests that, in the a b s e n c e of axonal injury, clinical resolution after B12 m a y precede normalization of increased T2-weighted signal on MRI, which reflects e d e m a of myelin sheaths. Overall, our study raises the possibility t h a t MRI findings at the time of diagnosis could be potential correlates of outcome a n d have a prognostic value in s u b a c u t e combined degeneration.
While the majority of patients in o u r study h a d pernicious anemia, our findings suggest t h a t the a b s e n c e of a n e m i a was associated with higher rates of resolution of neurologic deficits after B 12 therapy. This finding was surprising as the severity of hematological changes in subjects with pernicious anemia does not appear to correlate with neurological eomplica-tions. 2"6° Aiso, among the factors analyzed, laboratory markers of pernicious anemia had weaker associations with resolution of signs and symptoms. In addition, all patients reported with subacute combined degeneration had some improvement with BI2 therapy despite variability of regimens. These findings, along with MRI and the clinical factors described above, suggest that lesser disease severity and duration, rather than etiology, is associated with complete resolution of signs and symptoms of subacute combined degeneration.
Of interest, 15 of 57 patients included in this study developed subacute combine degeneration after exposure to nitrous oxide either during a general anesthetic or after chronic use as a recreational drug. It is known that nitrous oxide affects vitamin B 12 metabolism by oxidizing its reduced form.
In turn, as the reduced form of BI2, a coenzyme for methionine synthase, is oxidized, methionine synthase is inhibited by deprivation of the reduced form of B12. Consequently, the transmethylation of homocysteine to methionine catalyzed by methionine synthase is impaired, which in turn can ultimately impact on DNA, myelin, and catecholamine synthesis. 63 Given that recreational use of nitrous oxide appears to be gaining popularity, recognition that exposure to the drug can lead to subacute combined degeneration is important. In addition, in patients with newly diagnosed myelopathy, the possibility of nitrous oxide abuse should be explored as cessation of exposure is necessary for successful therapy. 63
Although our study generates valuable information that should be further evaluated in future studies, it has limitations. They include its retrospective nature, uncontrollable variability of diagnostic criteria and treatment regimens, number of treating centers, and lack of standardized tools to measure outcomes and standard follow-ups. While informative and the first to suggest that clinical and radiological findings at the time of diagnosis can potentially correlate with resolution of neurologic deficits, our study simply generates hypotheses about the biology of subacute combined degeneration that warrant further testing. Nevertheless, our findings suggest that young patients with less severe neurologic deficits, less extensive spinal cord lesions on MRI, who are treated earlier in the course of the disease, are likely to have higher resolution rates of signs and symptoms caused by subacute combined degeneration.
